WO2014026189A3 - Production and utilization of a novel anti-cancer drug in therapy - Google Patents

Production and utilization of a novel anti-cancer drug in therapy Download PDF

Info

Publication number
WO2014026189A3
WO2014026189A3 PCT/US2013/054530 US2013054530W WO2014026189A3 WO 2014026189 A3 WO2014026189 A3 WO 2014026189A3 US 2013054530 W US2013054530 W US 2013054530W WO 2014026189 A3 WO2014026189 A3 WO 2014026189A3
Authority
WO
WIPO (PCT)
Prior art keywords
mirna
mir
cells
human
vaccines
Prior art date
Application number
PCT/US2013/054530
Other languages
French (fr)
Other versions
WO2014026189A2 (en
WO2014026189A4 (en
Inventor
Shi-Lung Lin
David TS WU
Original Assignee
Shi-Lung Lin
Wu David Ts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/572,263 external-priority patent/US20130210120A1/en
Application filed by Shi-Lung Lin, Wu David Ts filed Critical Shi-Lung Lin
Priority to JP2015526754A priority Critical patent/JP2015530988A/en
Priority to CN201380042546.7A priority patent/CN105143459B/en
Priority to EP13827192.9A priority patent/EP2882859A4/en
Publication of WO2014026189A2 publication Critical patent/WO2014026189A2/en
Publication of WO2014026189A3 publication Critical patent/WO2014026189A3/en
Publication of WO2014026189A4 publication Critical patent/WO2014026189A4/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

This invention generally relates to a design and method for developing novel anti-tumor and/or anti-cancer drugs, vaccines and therapies, using microRNA and/or its shRNA homologues/mimics/derivatives. More specifically, the present invention relates to an use of a prokaryote-produced miRNA precursor (pro-miRNA) composition capable of being delivered into human cells and processed by the cells into mature miRNA effectors to elicit specific silencing effects on mir-302-targeted genes, subsequently leading to a beneficial result of tumor suppression and cancer therapy. The prokaryotic cells do not naturally express or process eukaryotic miRNA precursors (pre-miRNA); meanwhile, the present invention also teaches an inducible method for expressing pre-miRNAs, particularly mir-302 precursors by using the prokaryotic transcription system. Since mir-302 is a known tumor suppressor in human, this novel finding advances the design and method for developing new anti-cancer drugs, vaccines and/or therapies directed against multiple kinds of human tumors and cancers.
PCT/US2013/054530 2012-08-10 2013-08-12 Production and utilization of a novel anti-cancer drug in therapy WO2014026189A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2015526754A JP2015530988A (en) 2012-08-10 2013-08-12 Production and use of new therapeutic anticancer drugs
CN201380042546.7A CN105143459B (en) 2012-08-10 2013-08-12 Manufacture and use of novel therapeutic anticancer agents
EP13827192.9A EP2882859A4 (en) 2012-08-10 2013-08-12 Production and utilization of a novel anti-cancer drug in therapy

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13/572,263 2012-08-10
US13/572,263 US20130210120A1 (en) 2011-08-12 2012-08-10 Inducible Gene Expression Composition for Using Eukaryotic Pol-2 Promoter-Driven Transcription in Prokaryotes and the Applications Thereof
US201261746786P 2012-12-28 2012-12-28
US61/746,786 2012-12-28
US201361761890P 2013-02-07 2013-02-07
US61/761,890 2013-02-07

Publications (3)

Publication Number Publication Date
WO2014026189A2 WO2014026189A2 (en) 2014-02-13
WO2014026189A3 true WO2014026189A3 (en) 2014-05-01
WO2014026189A4 WO2014026189A4 (en) 2014-06-19

Family

ID=50068735

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/054530 WO2014026189A2 (en) 2012-08-10 2013-08-12 Production and utilization of a novel anti-cancer drug in therapy

Country Status (4)

Country Link
EP (1) EP2882859A4 (en)
JP (3) JP2015530988A (en)
CN (1) CN105143459B (en)
WO (1) WO2014026189A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017095489A1 (en) * 2015-12-02 2017-06-08 Shi-Lung Lin Use of microrna precursors as drugs for inducing cd34-positive adult stem cell expansion
US20200318110A1 (en) * 2016-05-27 2020-10-08 Lin Shi Lung A composition and method of using mir-302 precursors as anti-cancer drugs for treating human lung cancer
CN107913284B (en) * 2016-10-09 2022-09-16 上海市东方医院 Application of miRNA302-367 cluster microRNA in targeted inhibition of angiogenesis and tumor growth

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100240126A1 (en) * 2008-05-07 2010-09-23 Shi-Lung Lin Development of universal cancer drugs and vaccines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2229444B1 (en) * 2008-01-16 2019-10-30 Shi-Lung Lin Generation of tumor-free embryonic stem-like pluripotent cells using inducible recombinant rna agents
JP6185468B2 (en) * 2011-08-12 2017-08-23 メロ バイオテクノロジー インコーポレイテッドＭｅｌｌｏ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ，Ｉｎｃ． Methods and compositions for expressing hairpin-like RNA in prokaryotic cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100240126A1 (en) * 2008-05-07 2010-09-23 Shi-Lung Lin Development of universal cancer drugs and vaccines
WO2011025566A1 (en) * 2009-08-26 2011-03-03 Shi-Lung Lin Development of universal cancer drugs and vaccines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOTA, J ET AL.: "Therapeutic microRNA Delivery Suppresses Tumorigenesis In A Murine Liver Cancer Model.", CELL., vol. 137, 12 June 2009 (2009-06-12), pages 1005 - 1017, XP055004118 *
SIBLEY, CR ET AL.: "Novel RNA-Sased Strategies For Therapeutic Gene Silencing.", THE AMERICAN SOCIETY OF GENE & CELL THERAPY., vol. 18, 19 January 2010 (2010-01-19), pages 466 - 476, XP055004655 *

Also Published As

Publication number Publication date
JP2018016633A (en) 2018-02-01
CN105143459A (en) 2015-12-09
JP2020037599A (en) 2020-03-12
WO2014026189A2 (en) 2014-02-13
EP2882859A2 (en) 2015-06-17
EP2882859A4 (en) 2016-04-13
CN105143459B (en) 2020-04-14
JP2015530988A (en) 2015-10-29
WO2014026189A4 (en) 2014-06-19

Similar Documents

Publication Publication Date Title
Anfossi et al. MicroRNAs, regulatory messengers inside and outside cancer cells
Paladini et al. Targeting microRNAs as key modulators of tumor immune response
Parasramka et al. MicroRNAs, diet, and cancer: new mechanistic insights on the epigenetic actions of phytochemicals
Xu et al. microRNA regulation of human pancreatic cancer stem cells
WO2014117050A3 (en) Modified mirna as a scaffold for shrna
Li et al. MiRNA-based therapeutic strategy in lung cancer
EP4233874A3 (en) Acetylsalicylic acid for reducing the risk of a thromboembolic event
Donzelli et al. MicroRNAs: non-coding fine tuners of receptor tyrosine kinase signalling in cancer
WO2013090523A3 (en) Methods, systems, and compositions for cell-derived/vesicle-based microrna delivery
WO2014026189A3 (en) Production and utilization of a novel anti-cancer drug in therapy
NZ735160A (en) Cell therapeutic agent for cancer treatment and combination therapy with same
Huang et al. Construction of HCC-targeting artificial miRNAs using natural miRNA precursors
Ishikawa et al. Anesthetics may modulate cancer surgical outcome: a possible role of miRNAs regulation
Salamati et al. Modulation of telomerase expression and function by miRNAs: anti-cancer potential
Mortazavi et al. Epi-miRNAs: Regulators of the histone modification machinery in human cancer
MX2016010177A (en) Antica.
MX2013011694A (en) Taxane and abeo-taxane analogs.
AU2012325682A8 (en) Microalgal extraction
WO2013112523A3 (en) Down-regulation of gene expression using artificial micrornas for silencing fatty acid biosynthestic genes
WO2012135814A3 (en) Microrna29a,b,c as a tumor suppressor and sensitizing agent for chemotherapy
Samson et al. Prospects of microRNAs as therapeutic biomarkers in non-small cell lung cancer
BR112018010292A2 (en) treatment of central nervous tumors
AU2013296083A8 (en) Process for producing alcohol by fermentation of sugars
Juneja et al. MicroRNAs and noncoding RNAs as gene regulators and potential therapeutic agents
Tian et al. Roles of miRNAs in regulating the differentiation and maturation of myeloid-derived suppressor cells

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201380042546.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13827192

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2015526754

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013827192

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13827192

Country of ref document: EP

Kind code of ref document: A2